Research programme: Alzheimer's disease therapeutics - Senexis

Drug Profile

Research programme: Alzheimer's disease therapeutics - Senexis

Alternative Names: SEN1176; SEN1500; SEN1576; SEN304; SEN606

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Senexis
  • Class Peptides; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Macrophage inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
  • 22 Feb 2011 Preclinical development is ongoing in United Kingdom
  • 13 Nov 2010 Pharmacodynamics data from a preclinical trial in Alzheimer's disease presented at the 40th Annual Meeting of the Society for Neuroscience (SFN-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top